All In Biotech

Drug Trial Radar · NCT00168662

Non-Specific Effects of Standard Titre Measles Vaccination

Trial of Two-Dose Standard Measles Vaccination Schedule: Long-Term Impact on Morbidity and Mortality of a Two-Dose Vaccination Schedule at 6 and 9 Months of Age Compared With a Standard Regimen of One Dose at 9 Months of Age

Last checked: Nov 20, 2026Latest source record: Feb 26, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 7,800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,800

Actual

Start

Mar 1995

Primary completion

Jan 2006

Study completion Jan 2006

Sponsor

Lead sponsor
Bandim Health ProjectAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
International Cooperation with Developing Countries; Danish Council for Development Research; Medical Research Council Unit, The Gambia
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 6 months, up to 8 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The general objectives of the proposed research work are: A1) to reduce childhood mortality in developing countries through better control of measles infection by finding the best immunization strategy, and A2) to investigate the hypothesis that standard titre measles immunization is associated with non targeted beneficial effects on childhood morbidity and mortality in developing countries. The measurable, specific objectives of the present proposal are: B1) to examine whether a two-dose strategy for measles immunization at 6 and 9 months of age can reduce measles incidence by 50% through better coverage or improved seroconversion, and B2) to examine whether a two-dose strategy for measles immunization at 6 and 9 months of age can reduce childhood mortality by 20% through better coverage, better protection against measles or non targeted beneficial effects, and B3) to determine the magnitude and duration of non-measles related changes in morbidity patterns after standard titre measles immunization, in particular to test whether measles immunization is associated with a 15% reduction in the risk of diarrhoea, and B4) to determine non-measles related immunological changes among recipients of measles vaccine in order to establish possible pathways for the non targeted effects of standard titre measles immunization.

Conditions

  • Measles

Interventions

  • Measles and inactivated polio vaccineBiological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Vaccination coverage
  2. Vaccine efficacy
  3. Measles specific mortality
  4. All cause mortality until 3 years of age

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bandim Health Project

    Bissau, Apartado 861, Guinea-Bissau

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.